Sec.		Sec.
350.	Vitamins and minerals.	360l. Postmarket surveillance.
350a.	Infant formulas.	360m. Accredited persons.
350b.	New dietary ingredients.	360n. Priority review to encourage treatments for
350c.	Maintenance and inspection of records.	tropical diseases.
350d. 350e.	Registration of food facilities. Sanitary transportation practices.	360n-1. Priority review for qualified infectious disease products.
350e.	Reportable food registry.	ease products.
350g.	Hazard analysis and risk-based preventive	PART B—DRUGS FOR RARE DISEASES OR CONDITIONS
	controls.	360aa. Recommendations for investigations of drugs
350h.	Standards for produce safety.	for rare diseases or conditions.
350i.	Protection against intentional adulteration.	360bb. Designation of drugs for rare diseases or con-
350j.	Targeting of inspection resources for domes-	ditions.
	tic facilities, foreign facilities, and ports of	360cc. Protection for drugs for rare diseases or con-
350k.	entry; annual report.  Laboratory accreditation for analyses of	ditions.
550K.	foods.	360dd. Open protocols for investigations of drugs for
3501.	Mandatory recall authority.	rare diseases or conditions.
350 <i>l</i> –1.	Annual report to Congress.	360ee. Grants and contracts for development of drugs for rare diseases and conditions.
SI	UBCHAPTER V—DRUGS AND DEVICES	360ff. Priority review to encourage treatments for
Σ.		rare pediatric diseases.
	PART A—DRUGS AND DEVICES	•
351.	Adulterated drugs and devices.	PART C—ELECTRONIC PRODUCT RADIATION CONTROL
352.	Misbranded drugs and devices.	360hh. Definitions.
353.	Exemptions and consideration for certain	360ii. Program of control.
	drugs, devices, and biological products.	360jj. Studies by Secretary.
353a.	Pharmacy compounding.	360kk. Performance standards for electronic prod-
353a-1.	Enhanced communication.	ucts.
353b. 353c.	Outsourcing facilities. Prereview of television advertisements.	360ll. Notification of defects in and repair or re-
354.	Veterinary feed directive drugs.	placement of electronic products.
355.	New drugs.	360mm. Imports. 360nn. Inspection, records, and reports.
355–1.	Risk evaluation and mitigation strategies.	36000. Prohibited acts.
355a.	Pediatric studies of drugs.	360pp. Enforcement.
355b.	Adverse-event reporting.	360qq. Repealed.
355c.	Research into pediatric uses for drugs and bi-	360rr. Federal-State cooperation.
	ological products.	360ss. State standards.
355c-1.	Report.	PART D—DISSEMINATION OF TREATMENT INFORMATION
355d.	Internal committee for review of pediatric plans, assessments, deferrals, deferral ex-	
	tensions, and waivers.	360aaa to 360aaa–6. Omitted
355e.	Pharmaceutical security.	PART E—GENERAL PROVISIONS RELATING TO DRUGS
355f.	Extension of exclusivity period for new quali-	AND DEVICES
	0: 1: 0 4: 1: 1	
	fied infectious disease products.	360bbb Expanded access to unapproved therapies and
356.	Expedited approval of drugs for serious or	360bbb. Expanded access to unapproved therapies and diagnostics.
	Expedited approval of drugs for serious or life-threatening diseases or conditions.	360bbb. Expanded access to unapproved therapies and diagnostics. 360bbb-1. Dispute resolution.
356. 356–1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority counter-	diagnostics.
356–1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in
356–1. 356a.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies.
356–1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products.
356–1. 356a. 356b.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use.
356-1. 356a. 356b. 356c. 356c-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and
356-1. 356a. 356b. 356c. 356c-1. 356d.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance.
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.	diagnostics.  360bbb-1. Dispute resolution.  360bbb-2. Classification of products.  360bbb-3. Authorization for medical products for use in emergencies.  360bbb-3a.Emergency use of medical products.  360bbb-3b.Products held for emergency use.  360bbb-4. Countermeasure development, review, and technical assistance.  360bbb-5. Critical Path Public-Private Partnerships.
356-1. 356a. 356b. 356c. 356c-1. 356d. 356e. 356f.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance.
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e. 356f. 357.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication.
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e. 356f. 357. 358.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.	diagnostics.  360bbb-1. Dispute resolution.  360bbb-2. Classification of products.  360bbb-3. Authorization for medical products for use in emergencies.  360bbb-3a.Emergency use of medical products.  360bbb-3b.Products held for emergency use.  360bbb-4. Countermeasure development, review, and technical assistance.  360bbb-5. Critical Path Public-Private Partnerships.  360bbb-6. Risk communication.  360bbb-7. Notification.  360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e. 356f. 357. 358. 359.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.	diagnostics.  360bbb-1. Dispute resolution.  360bbb-2. Classification of products.  360bbb-3. Authorization for medical products for use in emergencies.  360bbb-3a.Emergency use of medical products.  360bbb-3b.Products held for emergency use.  360bbb-4. Countermeasure development, review, and technical assistance.  360bbb-5. Critical Path Public-Private Partnerships.  360bbb-6. Risk communication.  360bbb-7. Notification.  360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e. 356f. 357. 358.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials.
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e. 356f. 357. 358. 359. 360.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.  Registration of producers of drugs or devices.  Clinical trial guidance for antibiotic drugs.  Clinical trials.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3b.Products held for emergency use. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from out-
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e. 356f. 357. 358. 359. 360. 360a. 360a–1. 360b.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.  Registration of producers of drugs or devices.  Clinical trial guidance for antibiotic drugs.  New animal drugs.	diagnostics.  360bbb-1. Dispute resolution.  360bbb-2. Classification of products.  360bbb-3. Authorization for medical products for use in emergencies.  360bbb-3a.Emergency use of medical products.  360bbb-3b.Products held for emergency use.  360bbb-4. Countermeasure development, review, and technical assistance.  360bbb-5. Critical Path Public-Private Partnerships.  360bbb-6. Risk communication.  360bbb-7. Notification.  360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.  360bbb-8a.Optimizing global clinical trials.  360bbb-8b.Use of clinical investigation data from outside the United States.
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e. 356f. 357. 358. 359. 360a. 360a–1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.  Registration of producers of drugs or devices.  Clinical trials guidance for antibiotic drugs.  Clinical trials.  New animal drugs.  Classification of devices intended for human	diagnostics.  360bbb-1. Dispute resolution.  360bbb-2. Classification of products.  360bbb-3. Authorization for medical products for use in emergencies.  360bbb-3a.Emergency use of medical products.  360bbb-3b.Products held for emergency use.  360bbb-4. Countermeasure development, review, and technical assistance.  360bbb-5. Critical Path Public-Private Partnerships.  360bbb-6. Risk communication.  360bbb-7. Notification.  360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.  360bbb-8a.Optimizing global clinical trials.  360bbb-8b.Use of clinical investigation data from outside the United States.
356–1. 356a. 356b. 356c. 356c–1. 356d. 356e. 356f. 357. 358. 359. 360. 360a. 360a.–1. 360b. 360c.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use.	diagnostics.  360bbb-1. Dispute resolution.  360bbb-2. Classification of products.  360bbb-3. Authorization for medical products for use in emergencies.  360bbb-3a.Emergency use of medical products.  360bbb-3b.Products held for emergency use.  360bbb-4. Countermeasure development, review, and technical assistance.  360bbb-5. Critical Path Public-Private Partnerships.  360bbb-6. Risk communication.  360bbb-7. Notification.  360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.  360bbb-8a.Optimizing global clinical trials.  360bbb-8b.Use of clinical investigation data from outside the United States.  360bbb-8c.Patient participation in medical product discussion.
356-1. 356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360a. 360a-1. 360b. 360c-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting.	diagnostics.  360bbb-1. Dispute resolution.  360bbb-2. Classification of products.  360bbb-3. Authorization for medical products for use in emergencies.  360bbb-3a.Emergency use of medical products.  360bbb-3b.Products held for emergency use.  360bbb-4. Countermeasure development, review, and technical assistance.  360bbb-5. Critical Path Public-Private Partnerships.  360bbb-6. Risk communication.  360bbb-7. Notification.  360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.  360bbb-8a.Optimizing global clinical trials.  360bbb-8b.Use of clinical investigation data from outside the United States.  360bbb-8c.Patient participation in medical product discussion.  PART F—New Animal Drugs for Minor Use and
356-1. 356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360. 360a-1. 360b. 360c.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.  Registration of producers of drugs or devices.  Clinical trial guidance for antibiotic drugs.  Clinical trials.  New animal drugs.  Classification of devices intended for human use.  Reporting.  Performance standards.	diagnostics.  360bbb-1. Dispute resolution.  360bbb-2. Classification of products.  360bbb-3. Authorization for medical products for use in emergencies.  360bbb-3a.Emergency use of medical products.  360bbb-3b.Products held for emergency use.  360bbb-4. Countermeasure development, review, and technical assistance.  360bbb-5. Critical Path Public-Private Partnerships.  360bbb-6. Risk communication.  360bbb-7. Notification.  360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.  360bbb-8a.Optimizing global clinical trials.  360bbb-8b.Use of clinical investigation data from outside the United States.  360bbb-8c.Patient participation in medical product discussion.
356-1. 356a. 356b. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360. 360a. 360a. 360c. 360c-1. 360d. 360e.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.  Registration of producers of drugs or devices.  Clinical trial guidance for antibiotic drugs.  Clinical trials.  New animal drugs.  Classification of devices intended for human use.  Reporting.  Performance standards.  Premarket approval.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360cc. Conditional approval of new animal drugs for
356-1. 356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360. 360a-1. 360b. 360c.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.  Registration of producers of drugs or devices.  Clinical trial guidance for antibiotic drugs.  Clinical trials.  New animal drugs.  Classification of devices intended for human use.  Reporting.  Performance standards.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species.
356-1. 356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 360. 360a. 360a-1. 360b. 360c-1. 360d. 360c-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies.  Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan.  Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.  Registration of producers of drugs or devices.  Clinical trial guidance for antibiotic drugs.  Clinical trials.  New animal drugs.  Classification of devices intended for human use.  Reporting.  Performance standards.  Premarket approval.  Pediatric uses of devices.  Banned devices.  Judicial review.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new
356-1. 356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360a. 360a. 360a. 360c. 360c-1. 360d. 360e. 360e. 360e.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes.  Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages.  Coordination; task force and strategic plan. Drug shortage list.  Hospital repackaging of drugs in shortage.  Repealed.  Authority to designate official names.  Nonapplicability of subchapter to cosmetics.  Registration of producers of drugs or devices.  Clinical trial guidance for antibiotic drugs.  Clinical trials.  New animal drugs.  Classification of devices intended for human use.  Reporting.  Performance standards.  Premarket approval.  Pediatric uses of devices.  Banned devices.  Judicial review.  Agency documentation and review of signifi-	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species.
356-1. 356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360. 360a. 360a-1. 360b. 360c. 360c-1. 360f. 360e. 360e-1. 360f. 360g.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trials guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor use or
356-1.  356a. 356b. 356c.  356c-1. 356d. 356e. 356f. 357. 358. 369. 360a. 360a-1. 360b. 360c-1. 360d. 360e-1. 360g. 360g-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed.  Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species.
356-1. 356a. 356b. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360. 360a-1. 360b. 360c-1. 360d. 360e. 360e-1. 360f. 360g-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor use or
356-1. 356a. 356b. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360. 360a-1. 360b. 360c-1. 360d. 360e-1. 360f. 360g-1. 360g-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system. Records and reports on devices.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species. 360ccc-2. Designated new animal drugs for minor use or minor species.
356-1. 356a. 356b. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360. 360a-1. 360b. 360c-1. 360d. 360e. 360e-1. 360f. 360g-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species. 360ccc-2. Designated new animal drugs for minor use or minor species.  PART G—MEDICAL GASES 360ddd. Definitions.
356-1. 356a. 356b. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360. 360a-1. 360b. 360c-1. 360d. 360e-1. 360f. 360g-1. 360g-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system. Records and reports on devices. General provisions respecting control of devices intended for human use.	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species. 360ccc-2. Designated new animal drugs for minor use or minor species.
356-1. 356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 360. 360a. 360a-1. 360b. 360c. 360e-1. 360d. 360e-1. 360f. 360g. 360g-1.	Expedited approval of drugs for serious or life-threatening diseases or conditions.  Accelerated approval of priority countermeasures.  Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.  Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trials guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system. Records and reports on devices. General provisions respecting control of de-	diagnostics.  360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-7. Notification with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8a.Optimizing global clinical trials. 360bbb-8c.Patient participation in medical product discussion.  PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species. 360ccc-2. Designated new animal drugs for minor use or minor species.  PART G—MEDICAL GASES 360ddd. Definitions. 360ddd-1. Regulation of medical gases.

Sec. Part H–	-Pharmaceutical Distribution Supply Chain	Sec. 379j.	Authority to assess and use device fees.
360eee.	Definitions.	379j–1.	Reauthorization; reporting requirements.
	Requirements.  National standards for prescription drug		PART 4—FEES RELATING TO ANIMAL DRUGS
360eee–3.	wholesale distributors.  National standards for third-party logistics providers.	379j–11. 379j–12. 379j–13.	Definitions. Authority to assess and use animal drug fees. Reauthorization; reporting requirements.
360eee–4.	Uniform national policy.	SUBPAR	T 5—FEES RELATING TO GENERIC NEW ANIMAL
PART	I—Nonprescription Sunscreen and Other Active Ingredients	379j–21.	DRUGS Authority to assess and use generic new ani-
360fff.	Definitions.	379j–22.	mal drug fees. Reauthorization; reporting requirements.
360fff–1. 360fff–2.	Submission of requests. Eligibility determinations; data submission;	319J-22.	
360fff-3.	filing. GRASE determination.	379j–31.	SUBPART 6—FEES RELATED TO FOOD Authority to collect and use fees.
360fff-4.	Guidance; other provisions.	Ū	PART 7—FEES RELATING TO GENERIC DRUGS
360fff–5. 360fff–6.	Sunscreen monograph.  Non-sunscreen time and extent applications.	379j-41.	Definitions.
360fff–7.	Report. SUBCHAPTER VI—COSMETICS	379j–42.	Authority to assess and use human generic drug fees.
361.	Adulterated cosmetics.	379j–43.	Reauthorization; reporting requirements.
362. 363.	Misbranded cosmetics. Regulations making exemptions.	SUBPAR'	Γ 8—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS
364. SUI	Repealed. BCHAPTER VII—GENERAL AUTHORITY	379j–51. 379j–52.	Definitions. Authority to assess and use biosimilar bio-
	A—GENERAL ADMINISTRATIVE PROVISIONS	379j–53.	logical product fees. Reauthorization; reporting requirements.
371. 372.	Regulations and hearings. Examinations and investigations.	SUBPART	9—FEES RELATING TO OUTSOURCING FACILITIES
372a. 373.	Transferred. Records.	379j-61.	Definitions.
374.	Inspection.	379j–62.	Authority to assess and use outsourcing facility fees.
374a. 375.	Inspections relating to food allergens. Publicity.		PART D—INFORMATION AND EDUCATION
376.	Examination of sea food on request of packer;	379k.	Information system.
377.	marking food with results; fees; penalties. Revision of United States Pharmacopoeia; development of analysis and mechanical and	379k–1. 379 <i>l</i> .	Electronic format for submissions. Education.
	physical tests.	P	ART E—ENVIRONMENTAL IMPACT REVIEW
378. 379.	Advertising of foods. Confidential information.	379o.	Environmental impact.
379a. 379b.	Presumption of existence of jurisdiction.  Consolidated administrative and laboratory facility.	DRUGS	-NATIONAL UNIFORMITY FOR NONPRESCRIPTION AND PREEMPTION FOR LABELING OR PACKAG-COSMETICS
379c. 379d.	Transferred. Automation of Food and Drug Administra-	379r.	National uniformity for nonprescription drugs.
379d–1.	tion. Conflicts of interest.	379s.	Preemption for labeling or packaging of cosmetics.
379d–2.	Policy on the review and clearance of sci- entific articles published by FDA employ-		PART G—SAFETY REPORTS
379d–3.	ees. Streamlined hiring authority.	379v.	Safety report disclaimers.
379d–4.	Reporting requirements.		RT H—SERIOUS ADVERSE EVENT REPORTS
379d–5.	Guidance document regarding product promotion using the Internet.	379aa.	Serious adverse event reporting for non-
	PART B—Colors	379a.a_1	prescription drugs. Serious adverse event reporting for dietary
379e.	Listing and certification of color additives for foods, drugs, devices, and cosmetics.		supplements.  —Reagan-Udall Foundation for the Food
	PART C—FEES	FARTI	AND DRUG ADMINISTRATION
su	BPART 1—FREEDOM OF INFORMATION FEES	379dd.	Establishment and functions of the Foundation.
379f.	Recovery and retention of fees for freedom of information requests.		Location of Foundation. Activities of the Food and Drug Administra-
	SUBPART 2—FEES RELATING TO DRUGS		tion.
379g.	Definitions.		CHAPTER VIII—IMPORTS AND EXPORTS
379h. 379h–1.	Authority to assess and use drug fees. Fees relating to advisory review of prescrip-	381. 382.	Imports and exports.  Exports of certain unapproved products.
379h–2.	tion-drug television advertising. Reauthorization; reporting requirements.	383.	Office of International Relations.
		384. 384a.	Importation of prescription drugs. Foreign supplier verification program.
379i.	SUBPART 3—FEES RELATING TO DEVICES  Definitions.	384b. 384c.	Voluntary qualified importer program.  Inspection of foreign food facilities.
0101.	Dominiolons.	JUTO.	mapoconon or foreign food facilities.

Sec.				
384d.	Accreditation of third-party auditors.			
384e.	Recognition of foreign government inspections.			
SU	BCHAPTER IX—TOBACCO PRODUCTS			
387.	Definitions.			
387a.	FDA authority over tobacco products.			
387a-1.	Final rule.			
387b.	Adulterated tobacco products.			
387c.	Misbranded tobacco products.			
387d.	Submission of health information to the Secretary.			
387e.	Annual registration.			
387f.	General provisions respecting control of to- bacco products.			
387f–1.	Enforcement action plan for advertising and promotion restrictions.			
387g.	Tobacco product standards.			
387h.	Notification and other remedies.			
387i.	Records and reports on tobacco products.			
387j.	Application for review of certain tobacco products.			
387k.	Modified risk tobacco products.			
3871.	Judicial review.			
387m.	Equal treatment of retail outlets.			
387n.	Jurisdiction of and coordination with the Federal Trade Commission.			
3870.	Regulation requirement.			
387p.	Preservation of State and local authority.			
387q.	Tobacco Products Scientific Advisory Committee.			
387r.	Drug products used to treat tobacco dependence.			
387s.	User fees.			
387t.	Labeling, recordkeeping, records inspection.			
387u.	Studies of progress and effectiveness.			
SUBCHAPTER X—MISCELLANEOUS				
391.	Separability clause.			
392.	Exemption of meats and meat food products.			
393.	Food and Drug Administration.			
393a.	Office of Pediatric Therapeutics.			
394.	Scientific review groups.			
395.	Loan repayment program.			
396.	Practice of medicine.			
397.	Contracts for expert review.			
398.	Notices to States regarding imported food.			
399.	Grants to enhance food safety.			
399a.	Office of the Chief Scientist.			
399b.	Office of Women's Health.			
399c.	Improving the training of State, local, territorial, and tribal food safety officials.			
399d.	Employee protections.			
399e.	Nanotechnology.			
399f.	Ensuring adequate information regarding			
	pharmaceuticals for all populations, particularly underrepresented subpopulations,			

## SUBCHAPTER I—SHORT TITLE

including racial subgroups.

## § 301. Short title

This chapter may be cited as the Federal Food, Drug, and Cosmetic Act.

(June 25, 1938, ch. 675, §1, 52 Stat. 1040.)

EFFECTIVE DATE; POSTPONEMENT IN CERTAIN CASES

Act June 23, 1939, ch. 242, §§1, 2, 53 Stat. 853, 854, provided that:

"[Sec. 1] (a) The effective date of the following provisions of the Federal Food, Drug, and Cosmetic Act is hereby postponed until January 1, 1940: Sections 402(c) [342(c) of this title]; 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k) of this title]; 501(a), (4) [351(a)(4) of this title]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; 601(e) [361(e) of this title]; and 602(b) [362(b) of this title].

"(b) The Secretary of Agriculture shall promulgate regulations further postponing to July 1, 1940[,] the effective date of the provisions of sections 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k)]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; and 602(b) [362(b) of this title] of such Act with respect to lithographed labeling which was manufactured prior to February 1, 1939, and to containers bearing labeling which, prior to February 1, 1939, was lithographed, etched, stamped, pressed, printed, fused or blown on or in such containers, where compliance with such provisions would be unduly burdensome by reason of causing the loss of valuable stocks of such labeling or containers, and where such postponement would not prevent the public interest being adequately served: Provided, That in no case shall such regulations apply to labeling which would not have complied with the requirements of the Food and Drugs Act of June 30, 1906, as amended.

"Sec. 2. (a) The provisions of section 8 [section 10 of this title], paragraph fifth, under the heading 'In the case of food:', of the Food and Drugs Act of June 30, 1906, as amended, and regulations promulgated thereunder, and all other provisions of such Act to the extent that they may relate to the enforcement of such section 8 [section 10 of this title] and of such regulations, shall remain in force until January 1, 1940.

(b) The provisions of such Act of June 30, 1906, as amended, [sections 1 to 5, 7 to 15, and 372a of this title] to the extent that they impose, or authorize the imposition of, any requirement imposed by section 403(k) of the Federal Food, Drug, and Cosmetic Act [section 343(k) of this title], shall remain in force until January 1, 1940.

"(c) Notwithstanding the provisions of section 1 of this Act, such section shall not apply—
"(1) to the provisions of section 502(d) and (e) of the

Federal Food, Drug, and Cosmetic Act [352(d), (e) of this title], insofar as such provisions relate to any substance named in section 8 [section 10 of this title], paragraph second, under the heading 'In the case of drugs:', of the Food and Drugs Act of June 30, 1906, as amended, or a derivative of any such substance; or

"(2) to the provisions of section 502(b), (d), (e), (f), (g), and (h) of the Federal Food, Drug, and Cosmetic Act [352(b), (d) to (h) of this title], insofar as such provisions relate to drugs to which section 505 [355 of this title] of such Act applies.'

## EFFECTIVE DATE

Act June 25, 1938, ch. 675, 1002(a), formerly 902(a), 52 Stat. 1059; renumbered §1002(a), Pub. L. 111-31, div. A, title I, §101(b)(2), June 22, 2009, 123 Stat. 1784, provided that: "This Act [enacting this chapter and repealing sections 1 to 5 and 7 to 15 of this title], shall take effect twelve months after the date of its enactment [June 25, 1938]. The Federal Food and Drugs Act of June 30, 1906, as amended (U.S.C., 1934 ed., title 21, secs. 1-15), shall remain in force until such effective date, and, except as otherwise provided in this subsection, is hereby repealed effective upon such date: Provided, That the provisions of section 701 [section 371 of this title] shall become effective on the enactment of this Act, and thereafter the Secretary is authorized hereby to (1) conduct hearings and to promulgate regulations which shall become effective on or after the effective date of this Act as the Secretary shall direct, and (2) designate prior to the effective date of this Act food having common or usual names and exempt such food from the requirements of clause (2) of section 403(i) [section 343(i) of this title] for a reasonable time to permit the formulation, promulgation, and effective application of definitions and standards of identity therefor as provided by section 401 [section 341 of this title]: Provided further, That sections 502(j), 505, and 601(a) [sections 352(j), 355, 361(a), respectively of this title], and all other provisions of this Act to the extent that they may relate to the enforcement of such sections, shall take effect on the date of the enactment of this Act, except that in the case of a cosmetic to which the proviso of section